CClinicalTrials.gg
CompletedNCT01366742Updated May 17, 2016

Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women

An observational study in Human Papillomavirus, CIN 2 and CIN 3, sponsored by University of California, Los Angeles. Completed at 2 sites in United States. Open to female participants aged 13 Years to 22 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-17.

Sponsored by University of California, Los Angeles · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Ages
13 Years to 22 Years
Sex
Female
01

Study summary

The natural history of human papillomavirus (HPV) is most likely influenced by both innate and adaptive mucosal immunity. More specifically, we hypothesize that Toll like receptors (TLR) play an important role in cervical innate immunity to HPV through secretions of proinflammatory, chemotactic and anti-viral cytokines. Up-regulated TLR expression will also result in activation of dendritic cells and T cells that in turn will promote a T helper (Th) l like response through secretion of several cytokines and consequently, the induction of a successful cell mediated immune (CMI) response.

Read the detailed description

The natural history of HPV is most likely influenced by both innate and adaptive mucosal immunity. More specifically, we hypothesize that Toll like receptors (TLRs) play an important role in cervical innate immunity to HPV through secretions of proinflammatory, chemotactic and anti-viral cytokines. Up-regulated TLR expression will also result in activation of dendritic cells and T cells that in turn will promote a Thl like response through secretion of several cytokines and consequently, the induction of a successful cell mediated immune (CMI) response.

We propose to: 1) examine, in cervical cell samples, the association among TRL expression, TRL-associated cytokines that mediate innate immunity and clearance of incident HPV infection; 2) examine, in cervical cell samples, the association among TRL expression, TRL-associated cytokines that induce and mediate adaptive immunity and HPV clearance; and 3) examine the association among TLR induced Th-1 responses measured in cervical cell samples, HPV specific CMI responses detected in peripheral blood (PB) and HPV clearance. Adolescent and young women who were a) entered into the cohort during the initial 1990-1995 period and have continued to be followed and b) entered into the cohort during the last recruitment wave (2000-2005) will be asked to continue followup for an additional five years (2005-2010). These women will have been well characterized at the time of the initiation of this study with HPV at their entry visit and 4-month interval sampling for HPV DNA, cytology, bacterial vaginosis, colpophotographs (assessment of cervical maturation), C. trachomatis and N. gonorrhea testing, cervical cell cytokines by reverse transcriptase polymerase chain reaction (RT-PCR) and peripheral blood (PB) CMI for HPV 16 positive women. Women will be continued to be characterized for the above at the same intervals through-out the follow-up. Measures of innate and adaptive immunity by RT PCR using cervical cells and by Luminex technology have been added to the same 4 month interval testing as HPV DNA, cytology and other cervical cytokines described. Women positive for HPV 16 will get additional blood for CMI using Interferon (IFN)-y Enzyme linked immunospot (EliSpot) technique for detection of anti-E6 and E7 responses. We also examine the natural history of anal HPV in these women. We acknowledge that this design simplifies the pleiotropic nature of cytokines. However, we feel that this model reflects plausible mechanisms involved in HPV control and is feasible to test in our cohort. Information garnered from this type of study will be critical in developing vaccine strategies and therapies as well as illuminating immune responses developed in the mucosal epithelium.

02

Conditions studied

  • Human Papillomavirus
  • CIN 2
  • CIN 3

Browse trials for

03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 900 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 22 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Community

Inclusion criteria

  • Age 12 to 22 years
  • Sexually active less than 6 years
  • Received one dose of the HPV vaccine

Exclusion criteria

Exclusion:

  • Planning on moving in 3 years
  • Prior history of treatment for CIN
  • Immunocompromised (ie transplant patient, HIV)
  • Pregnant
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • HPV Cohort

    Sexually active young women aged 12 to 22 years of age without a previous history of CIN. Women are not eligible for entry if pregnant or known immunosuppression.

06

What researchers measure

Primary outcomes

  1. Cervical Intraepithelial neoplasia (CIN) 2/3

    Observational study of women with HPV

    Time frame: 1990 to current

Secondary outcomes

  1. HPV persistence

    observational study of women with HPV

    Time frame: 1990 to present

07

Study locations

2 sites
  • SFSU Student Health Center
    San Francisco, California 94132, United States
  • HPV Study - San Leandro Office
    San Leandro, California 94577, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01366742
Lead sponsor
University of California, Los Angeles
Collaborators
National Institutes of Health (NIH), National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Jun 6, 2011
Start date
Dec 1987
Primary completion
May 2016
Completion
May 2016
Last update
May 17, 2016

Study contacts

Anna-Barbara Moscicki, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion